Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin

Viral Immunology

Volumn 13, Issue 1, 2000, Pages 49-56

  Drulak, Murray W ^a   Malinoski, Frank J ^a   Fuller, Steven A ^a   Stewart, Solomon S ^a   Hoskin, Somsong ^a   Duliege, Anne Marie ^b   Sekulovich, Rose ^b   Burke, Raelyn ^b   Winston, Scott ^a  

^a Nabi Biopharmaceuticals   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHIRON CMV GB; CYTOMEGALOVIRUS ANTIBODY; GLYCOPROTEIN; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; VACCINATION;

ANIMALIA; CHIRON; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; DNA VIRUSES;

EID: 0034061797     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2000.13.49     Document Type: Article

References (14)

1. Britt, W.J., L. Vugler, and E.B. Stephens. 1988. Induction of complement dependent and independent neutralizing antibodies by recombinant derived human cytomegalovirus gp55-116 (gB). J. Virol. 62:3309-3318.
2. Chou, S., and K.M. Dennison. 1991. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization related epitopes. J. Infect. Dis. 163:1229-1234.
3. Cummins, L.M., K.J. Weinhold, T.J. Matthews, A.J. Langlois, C.F. Perno, R.M. Condie, and J. Allain. 1991. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood 77:1111-1117.
4. Drew, W.L. 1992. Nonpulmonary manifestations of cytomegalovirus infection in immunocompromised patients. Clin. Microbiol. Rev. 5:204-210.
5. Hassfurther, E., W. Britt, and M. Mach. 1993. Mutational analysis of antigenic domain 1 (AD-1) of glycoprotein GP58 of human cytomegalovirus. In Michelson, S., S.A. Plotkin (eds): Multidisciplinary approach to understanding cytomegalvoirus disease. Elsevier Science Publ. B.V., Amsterdam; 43-47.
6. Horowitz, C.A., W. Henle, G. Henle, D. Snover, H. Rudnick, H.H. Balfour Jr., M.H. Mazur, R. Watson, B. Schwartz, and N. Muller. 1986. Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine 65:124-134.
7. Kari, B., N. Lussenhop, R. Goertz, M. Wabuke-Bunoti, R. Radeke, and R. Gehrz. 1986. Characterization of monoclonal antibodies reactive to several biochemically distinct human cytomegalovirus glycoprotein complexes. J. Virol. 60:345-353.
8. Oncley, J.L., M. Melin, D.A. Richert, J.W. Cameron, and P.M. Gross Jr. 1949. The separation of antibodies, isoagglutinins, prothrombin, plasminogen and beta-lipoprotein into subfractions of human plasma. J. Am. Chem. Soc. 713:541-550.
9. Plummer, G. 1973. Cytomegaloviruses of man and animals. Progr. Med Virol 15:92-125.
10. Povazhenko, A.A., Y.V. Sorokin, and E.P. Sorokina. 1986. Characteristics of the immune response to Staphylococcal anatoxin in healthy persons. Zh. Mikrobiol. Epidemiol. Immunobiol. 7:92-96.
11. Scott, J.R., H.B. Anstall, N.S. Rote, N.K. Kochenour, and J.H. Beeson. 1982. Effect of plasma exchange and immunosuppression on Rho(D), viral and bacterial antibody titers in Rh-immunized women. Am. J. Reprod. Immunol. 2:46-49.
12. van der Meer, J.T.M., W.L. Drew, R.A. Bowden, G.J., Galasso, P.D. Griffiths, D.A., Jabs, C. Katlama, S.A. Spector, and R.J. White. 1996. Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis of Cytomegalovirus Infection. Antiviral Res. 32:119-140.
13. Yoshida, H., K. Ito, T. Kusakari, K. Ida, Y. Ithara, T. Mori, and M. Matsumura. 1994. Removal of maternal antibodies from a woman with repeated fetal loss due to P blood group incompatibility. Transfusion 34:702-705.
14. Zaia, J.A. 1993. Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clin. Infect. Dis. 17 (Suppl 2):S392-399.